Non-alcoholic fatty liver disease (NAFLD) is a widespread contributor to chronic liver
disease globally. A recent consensus on renaming liver disease was established, and …

Metabolic dysfunction-associated steatotic liver disease (MASLD), once known as non-
alcoholic fatty liver disease (NAFLD), represents a spectrum of liver disorders characterized …

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly defined as non-
alcoholic fatty liver disease (NAFLD), is a disorder marked by the excessive deposition of …

Non-alcoholic liver disease (NAFLD) is now metabolic dysfunction-associated steatotic liver
disease (MASLD), emphasizing the key metabolic factors of obesity, insulin resistance …

Nonalcoholic fatty liver disease (NAFLD), a spectrum of metabolic liver disease associated
with obesity, ranges from relatively benign hepatic steatosis to nonalcoholic steatohepatitis …

Fatty liver disease is an emerging contributor to disease burden worldwide. The past
decades of work established the heterogeneous nature of non-alcoholic fatty liver disease …

Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an
important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing …

Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD), both of
them accounting for fatty liver disease (FLD), are among the most common chronic liver …

Non‐alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver
disease globally. Non‐alcoholic steatohepatitis (NASH) represents an extremely …

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic
liver disease globally and is currently estimated to affect up to 38% of the global adult …